Lancaster General Hospital | |
555 North Duke Street, Lancaster, Pennsylvania 17602 | |
(717) 544-5511 | |
Name | Lancaster General Hospital |
---|---|
Type | Acute Care Hospital |
Location | 555 North Duke Street, Lancaster, Pennsylvania |
Ownership | Voluntary non-profit - Other |
Emergency Services | Yes |
Medicare ID (CCN) | 390100 |
NPI Number | 1104875103 |
Organization Name | LANCASTER GENERAL HOSPITAL |
Address | 555 N Duke St, Lancaster, PA 17602 |
Hospital Type | General Acute Care Hospital |
Phone Number | 717-544-5511 |
News Archive
Perhaps due to lack of or inconsistent insurance coverage, young adults age 18 to 25 tend to go to the doctor's office less often than children or adolescents, yet have higher rates of emergency room use, finds a study in the Journal of Adolescent Health.
Science Exchange, in partnership with the world's largest marketplace for antibodies, antibodies-online, announced today the launch of a program to independently validate thousands of commercial antibodies via the Science Exchange independent validation service.
MannKind Corporation has announced that it has initiated patient enrollment in two pivotal 12-month Phase 3 clinical trials of Technosphere Insulin (TI) in patients with Type 1 and Type 2 Diabetes.
Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.
› Verified 3 days ago
NPI Number | 1205836046 |
Organization Name | SELECT SPECIALTY HOSPITAL - LANCASTER INC |
Address | 555 N Duke St, 4 North, Lancaster, PA 17602 |
Hospital Type | Long Term Care Hospital |
Phone Number | 717-544-5487 |
News Archive
Perhaps due to lack of or inconsistent insurance coverage, young adults age 18 to 25 tend to go to the doctor's office less often than children or adolescents, yet have higher rates of emergency room use, finds a study in the Journal of Adolescent Health.
Science Exchange, in partnership with the world's largest marketplace for antibodies, antibodies-online, announced today the launch of a program to independently validate thousands of commercial antibodies via the Science Exchange independent validation service.
MannKind Corporation has announced that it has initiated patient enrollment in two pivotal 12-month Phase 3 clinical trials of Technosphere Insulin (TI) in patients with Type 1 and Type 2 Diabetes.
Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.
› Verified 3 days ago
NPI Number | 1245571942 |
Organization Name | LANCASTER GENERAL HOSPITAL |
Doing Business As | PARKESBURG OUTPATIENT CENTER |
Address | 950 Octorara Trail, Parkesburg, PA 19365 |
Hospital Type | General Acute Care Hospital |
Phone Number | 717-544-5511 |
News Archive
Perhaps due to lack of or inconsistent insurance coverage, young adults age 18 to 25 tend to go to the doctor's office less often than children or adolescents, yet have higher rates of emergency room use, finds a study in the Journal of Adolescent Health.
Science Exchange, in partnership with the world's largest marketplace for antibodies, antibodies-online, announced today the launch of a program to independently validate thousands of commercial antibodies via the Science Exchange independent validation service.
MannKind Corporation has announced that it has initiated patient enrollment in two pivotal 12-month Phase 3 clinical trials of Technosphere Insulin (TI) in patients with Type 1 and Type 2 Diabetes.
Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.
› Verified 3 days ago
NPI Number | 1457585119 |
Organization Name | LANCASTER GENERAL HOSPITAL |
Doing Business As | HYPERBARIC WOUND AND CARE CENTER |
Address | 2100 Harrisburg Pike, Building 2112 Suite 327, Lancaster, PA 17601 |
Hospital Type | General Acute Care Hospital |
Phone Number | 717-544-3216 |
News Archive
Perhaps due to lack of or inconsistent insurance coverage, young adults age 18 to 25 tend to go to the doctor's office less often than children or adolescents, yet have higher rates of emergency room use, finds a study in the Journal of Adolescent Health.
Science Exchange, in partnership with the world's largest marketplace for antibodies, antibodies-online, announced today the launch of a program to independently validate thousands of commercial antibodies via the Science Exchange independent validation service.
MannKind Corporation has announced that it has initiated patient enrollment in two pivotal 12-month Phase 3 clinical trials of Technosphere Insulin (TI) in patients with Type 1 and Type 2 Diabetes.
Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.
› Verified 3 days ago
NPI Number | 1578999785 |
Organization Name | LANCASTER GENERAL HEALTH |
Address | 555 N Duke St, Lancaster, PA 17602 |
Hospital Type | General Acute Care Hospital |
Phone Number | 610-468-7773 |
News Archive
Perhaps due to lack of or inconsistent insurance coverage, young adults age 18 to 25 tend to go to the doctor's office less often than children or adolescents, yet have higher rates of emergency room use, finds a study in the Journal of Adolescent Health.
Science Exchange, in partnership with the world's largest marketplace for antibodies, antibodies-online, announced today the launch of a program to independently validate thousands of commercial antibodies via the Science Exchange independent validation service.
MannKind Corporation has announced that it has initiated patient enrollment in two pivotal 12-month Phase 3 clinical trials of Technosphere Insulin (TI) in patients with Type 1 and Type 2 Diabetes.
Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.
› Verified 3 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Perhaps due to lack of or inconsistent insurance coverage, young adults age 18 to 25 tend to go to the doctor's office less often than children or adolescents, yet have higher rates of emergency room use, finds a study in the Journal of Adolescent Health.
Science Exchange, in partnership with the world's largest marketplace for antibodies, antibodies-online, announced today the launch of a program to independently validate thousands of commercial antibodies via the Science Exchange independent validation service.
MannKind Corporation has announced that it has initiated patient enrollment in two pivotal 12-month Phase 3 clinical trials of Technosphere Insulin (TI) in patients with Type 1 and Type 2 Diabetes.
Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.
› Verified 3 days ago
Lancaster General Hospital Acute Care Hospital Location: 555 North Duke Street, Lancaster, Pennsylvania 17602 Phone: (717) 544-5511 | |
Lancaster Behavioral Health Hospital Psychiatric Hospital Location: 333 Harrisburg Avenue, Lancaster, Pennsylvania 17603 Phone: (717) 740-4100 |